Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EarlySense Patient Monitoring System Saw 40 Percent Increase in Adoption in 2016

XTALKS VITALS NEWS

Patient

The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

Share this!

January 25, 2017 | by Sarah Hand, M.Sc.

In 2016, adoption of the EarlySense continuous medical monitoring system increased by almost 40 percent, to include over 105 clinical care areas around the world. The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

According to statistically analysis conducted by EarlySense, the company estimates that their monitoring system may have helped save more than 550 lives, and prevent 800 falls and over 45,000 hospitalization days. In the absence of EarlySense monitoring and alerts, these events would cost a combined $30 million.

“In 2016, EarlySense significantly expanded the reach and impact of our hospital-proven technology and we are pleased to achieve these milestones,” said Avner Halperin, Founder and CEO of EarlySense. “Almost daily we hear from medical institutions about how they saved a life or dramatically improved a patient's outcome by leveraging EarlySense – it is extremely rewarding. It is clear that continuous monitoring is poised to become a global standard of care, and we look forward to providing valuable health insight and support to facilities, health teams and patients in 2017 and beyond.”



EarlySense has since made some upgrades to it continuous monitoring medical devices. The company launched InSight, a product aimed at reducing patient falls and hospital admissions in nursing facilities. A new Multi-Parameter Alert was also introduced, which monitors a patient’s heart and breathing rates to help healthcare providers in the early detection of sepsis.

“Non-ICU patients are at risk for a variety of complications during hospitalization and early warning signs are often subtle and not easily detected,” said Halperin. “By providing healthcare professionals with continuous data and timely indication of change through our Multi-Parameter Alert, precious time can be saved enabling early detection and treatment of sepsis as well as other potential adverse events.”

EarlySense is also breaking into the consumer health space by introducing its LIVE health monitoring solution. LIVE is primarily a sleep monitor, which EarlySense claims is the first consumer health monitoring product to be based on medically-proven technology.


Keywords: Patient Monitoring, Medical Device, Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.